Citi has increased its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 whilst maintaining a neutral rating on the pharmaceutical group following a notable rally in the shares driven
All posts tagged in Citi research
1Article
Citi has increased its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 whilst maintaining a neutral rating on the pharmaceutical group following a notable rally in the shares driven
